Nomura retained a Buy rating for Gland Pharma Ltd, citing its pivot to a CDMO model.
1 report, 1 independent
Updated Wed 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nomura retained a Buy rating for Gland Pharma Ltd, citing its pivot to a CDMO model.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Nomura
corporation in Japan
Related events
- Nomura reaffirmed its 'Buy' rating and target price for Lupin Limited.
- Nomura retained a buy rating, Morgan Stanley retained equal-weight, and CLSA downgraded Godrej Consumer Products stock.
- Nomura upgraded the stock rating for Toto Ltd. on September 4, 2026.
- Nomura is a Japanese financial services holding company.
- Nomura updated its ratings on several companies on September 2, 2026, including retaining a Neutral rating on Maruti Suzuki, noting Bajaj Auto was ahead of estimates, and retaining a Buy rating on Hyundai Motor India.